GlaxoSmithKline PLC
(GSK.L,
GSK)
Cabenuva (resubmitted NDA)
Mid 2021
FDA decision on Cabenuva to treat HIV-1 infection in adults whose viral load is suppressed and who are not resistant to cabotegravir or rilpivirine.
FDA approved Cabenuva on Jan.21, 2021-
Esbriet (sNDA)
May 2021
FDA decision on Esbriet for the treatment of unclassifiable interstitial lung disease
-
Avacopan (NDA)
05/06/2021
FDA panel to review Avacopan for the treatment of ANCA-associated vasculitis,
-